Article Sidebar

PDF
Date Published: 31/07/2021
Abstract Views: 267
Views PDF: 140
DOI: https://doi.org/10.51298/vmj.v502i2.625
Issue
Vol. 502 No. 2 (2021)
Section
Các bài báo
How to Cite
Thị Thái Hoà, N. ., & Thanh Huyền, M. . (2021). TREATMENT RESULTS OF PEMETREXED-CARBOPLATIN REGIMEN AS SECOND-LINE FOR NON–SMALL CELL LUNG CANCER AFTER EGFR TKIs ACCQUIRED RESISTANCE. Vietnam Medical Journal, 502(2). https://doi.org/10.51298/vmj.v502i2.625

TREATMENT RESULTS OF PEMETREXED-CARBOPLATIN REGIMEN AS SECOND-LINE FOR NON–SMALL CELL LUNG CANCER AFTER EGFR TKIs ACCQUIRED RESISTANCE

Nguyễn Thị Thái Hoà, Mai Thanh Huyền

Main Article Content

Abstract

Objective: To evaluate the treatment results of Pemetrexed - Carboplatin regimen in patients with non-small cell lung cancer after Tyrosin Kinase inhibitor accquired resistance. Objects and methods: Retrospective of 46 patients after accquired resistance to EGFR TKIs, on Pemetrexed - Carboplatin regimen, with longitudinal follow-up. Results: Rate of objective response 50%; complete response 0%; disease control 78.3%. Prognostic factors for poorer response: performance status PS1, stage IV, CNS metastasis. Median progression - free survival: 4 months. Conclusion: Pemetrexed - Carboplatin regimen is an appropriate treatment choice for patients with non-small cell lung cancer after resistance to Tyrosin Kinase inhibitors.

Article Details

Keywords

Non-small cell Lung cancer, accquired resistance, response rate, progression- free survival

References

1. Anh Thu Huynh Dang, et al (2020). Actionable Mutation Profles of non-Small cell Lung cancer patients from Vietnamese population. Scientific Reports, 10:2707 https://doi.org/10.1038/s41598-020-59744-3 5
2. Su KY, Chen HY, Li KC, et al (2012). Pretreatment epidermal growth factor receptor (EGFR) T790M mutation predicts shorter EGFR tyrosine kinase inhibitor response duration in patients with non-small-cell lung cancer. J Clin Oncol, 30(4):433. Epub 2012 Jan 3.
3.Tony S. Mok, Yi-Long Wu, Myung-Ju Ahn, et al (2017). Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer. New England journal o f Medicine, 376;7 , 629-40.
4. Mok TS, Wu YL, Thongprasert S, et al (2009). Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 361(10):947.
5. Lin C.-C., Hsu H.-H., Sun C.-T. và cộng sự. (2010). Chemotherapy Response in East Asian Non-small Cell Lung Cancer Patients Harboring Wild-Type or Activating Mutation of Epidermal Growth Factor Receptors. J Thorac Oncol, 5(9), 1424–1429
6. Scagliotti G.V. (2005). Pemetrexed plus carboplatin or oxaliplatin in advanced non small cell lung cancer. Semin Oncol, 32(2 Suppl 2), S5-8
7. Metro G., Chiari R., Mare M.et al. (2011). Carboplatin plus pemetrexed for platinum pretreated, advanced non-small cell lung cancer: a retrospective study with pharmacogenetic evaluation. Cancer Chemother Pharmacol, 68(6), 1405–1412.